|
PROSTATE CANCER TREATMENT EXPERT, DAVID B. SAMADI, MD, ANNOUNCES TRIFECTA BREAKTHROUGH
NEW YORK, NY--(Marketwire - March 28, 2008) - Dr. David B. Samadi, MD, Chief, Division of Robotics and Minimal Invasive Surgery at Mount Sinai Medical School in New York City, is in a unique position to hit a bulls-eye on behalf of his prostate cancer patients. He completed three specialized fellowships, providing ultimate surgical and healing outcome for those individuals combating prostate cancer. His surgical training incorporates the best techniques from open, laparoscopic, and robotic surgery. Each patient is evaluated individually by him and his surgical team to be sure of the best course of treatment. PSA level and PSA velocity are obtained as well as the volume of the cancer, and type of growth, be it a small nodule or a large tumor. From there, if an operation is indicated, then he prepares the patient for minimally invasive surgery. Although Dr. Samadi is a strong proponent of robotic surgery, he is prepared to use other approaches if necessary. If there is a technological breakdown in the robotic method, he is confident in his ability to continue the operation using laparoscopic or open surgery. This is where the first Trifecta model comes into play, i.e., the overlap of the three methods: open, laparoscopic, and robotic. Dr. Samadi is at the epicenter of the diagram, where he views himself and his training as "three surgeons in one head."
 
Even complex operations are completed within 90 minutes, which means patients' recovery is improved and less painful. The care for Dr. Samadi's patients with prostate cancer starts with the first initial consultation to the time when the patient is potent, continent, and fully cancer free. In order to achieve the Trifecta, patient care is individualized. He exclaims: "I don't believe in surprising my patients and I'm confident in my ability to provide the best prostate cancer treatment available in the world."
The second Trifecta is the overlapping outcome of cancer cure, continence, and potency. The epicenter of these three circles is the goal for the patient and Dr. Samadi. They want to have complete cancer cure, along with continence and potency. Dr. Samadi aims to hit the bulls-eye for every patient with these important post operative surgical goals. It is not enough for the patient to see results in one or two of these areas.
As the saying goes, practice makes perfect. With over 1,350 robotic prostate surgery operations completed by Dr. Samadi and his surgical team, patients should feel confident that they are receiving the highest standards of medical care available anywhere. Dr. Samadi also attributes his success to his hand picked surgical team, from scrub nurses to anesthesiologists to surgeons. He continues to point out his multiple surgical training provides an optimal combination of open, laparoscopic, and robotic techniques for the most favorable outcome in the operating room. "It's great to have access to state-of-the-art medical technology, but there is no substitute for proven open and laparoscopic surgical skills," concludes Dr. Samadi.
About David B. Samadi, M.D. & RoboticOncology.com
David B. Samadi, M.D. is Chief of Robotic Surgery and Minimal Invasive Surgery at Mount Sinai School of Medicine in New York City. He is a board certified Urologic Oncologist, specializing in the diagnosis and treatment of bladder, kidney, and prostate cancer using minimally invasive procedures like da Vinci surgery. If you would like more information about Dr. Samadi's state-of-the-art treatment options, including the robotic prostatectomy, please don't hesitate to call his office at 212-241-8779, or visit him on the web at http://www.roboticoncology.com.
|
